A comparative study of two different assay kits for the detection of secreted alkaline phosphatase in HPV antibody neutralization assays

References

• Cates W, Jr. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. american social health association panel. Sex Transm Dis 1999; 26:S2-7; PMID:10227693; http://dx.doi.org/10.1097/00007435-199904001-00002
   PubMed Web of Science ®Google Scholar
• Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010; 401:70-9; PMID:20206957; http://dx.doi.org/10.1016/j.virol.2010.02.002
   PubMed Web of Science ®Google Scholar
• Einstein MH, Schiller JT, Viscidi RP, Strickler HD, Coursaget P, Tan T, Halsey N, Jenkins D. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 2009; 9:347-56; PMID:19467474; http://dx.doi.org/10.1016/S1473-3099(09)70108-2
   PubMed Web of Science ®Google Scholar
• zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology 2009; 384:260-5; PMID:19135222; http://dx.doi.org/10.1016/j.virol.2008.11.046
   PubMed Web of Science ®Google Scholar
• Bosch FX, de Sanjose S. Chapter 1: human papillomavirus and cervical cancer–burden and assessment of causality. J Natl Cancer Inst Monogr 2003:3-13; PMID:12807939; http://dx.doi.org/10.1093/oxfordjournals.jncimonographs.a003479
   PubMedGoogle Scholar
• Castellsague X, Diaz M, de Sanjose S, Munoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders PJ, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006; 98:303-15; PMID:16507827; http://dx.doi.org/10.1093/jnci/djj067
   PubMed Web of Science ®Google Scholar
• Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-27; PMID:12571259; http://dx.doi.org/10.1056/NEJMoa021641
   PubMed Web of Science ®Google Scholar
• Roden R, Wu TC. How will HPV vaccines affect cervical cancer? Nat Rev Cancer 2006; 6:753-63; PMID:16990853; http://dx.doi.org/10.1038/nrc1973
   PubMed Web of Science ®Google Scholar
• Gardasil® ; [package insert]. United states food and drug administration. Initial approval 2006. Revised 03/2014. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111263.pdf. Accessed June 2014
   Google Scholar
• Cervarix® ; [package insert]. United states food and drug administration. Initial approval 2009. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM186981.pdf. Accessed June 2014
   Google Scholar
• Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30 5:F123-38; PMID:23199956; http://dx.doi.org/10.1016/j.vaccine.2012.04.108
   PubMed Web of Science ®Google Scholar
• Pastrana DV, Gambhira R, Buck CB, Pang YY, Thompson CD, Culp TD, Christensen ND, Lowy DR, Schiller JT, Roden RB. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology 2005; 337:365-72; PMID:15885736; http://dx.doi.org/10.1016/j.virol.2005.04.011
   PubMed Web of Science ®Google Scholar
• Gambhira R, Karanam B, Jagu S, Roberts JN, Buck CB, Bossis I, Alphs H, Culp T, Christensen ND, Roden RB. A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol 2007; 81:13927-31; PMID:17928339; http://dx.doi.org/10.1128/JVI.00936-07
   PubMedGoogle Scholar
• Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, Lowy DR, Schiller JT, Roden RB. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 2009; 101:782-92; PMID:19470949; http://dx.doi.org/10.1093/jnci/djp106
   PubMed Web of Science ®Google Scholar
• Jagu S, Kwak K, Karanam B, Huh WK, Damotharan V, Chivukula SV, Roden RB. Optimization of multimeric human papillomavirus L2 vaccines. PLoS One 2013; 8:e55538; PMID:23383218; http://dx.doi.org/10.1371/journal.pone.0055538
   PubMed Web of Science ®Google Scholar
• Bousarghin L, Combita-Rojas AL, Touze A, El Mehdaoui S, Sizaret PY, Bravo MM, Coursaget P. Detection of neutralizing antibodies against human papillomaviruses (HPV) by inhibition of gene transfer mediated by HPV pseudovirions. J Clin Microbiol 2002; 40:926-32; PMID:11880418; http://dx.doi.org/10.1128/JCM.40.3.926-932.2002
   PubMed Web of Science ®Google Scholar
• Touze A, Coursaget P. In vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res 1998; 26:1317-23; PMID:9469843; http://dx.doi.org/10.1093/nar/26.5.1317
   PubMed Web of Science ®Google Scholar
• Unckell F, Streeck RE, Sapp M. Generation and neutralization of pseudovirions of human papillomavirus type 33. J Virol 1997; 71:2934-9; PMID:9060652
   PubMed Web of Science ®Google Scholar
• Stauffer Y, Raj K, Masternak K, Beard P. Infectious human papillomavirus type 18 pseudovirions. J Mol Biol 1998; 283:529-36; PMID:9784363; http://dx.doi.org/10.1006/jmbi.1998.2113
   PubMed Web of Science ®Google Scholar
• Rossi JL, Gissmann L, Jansen K, Muller M. Assembly of human papillomavirus type 16 pseudovirions in saccharomyces cerevisiae. Hum Gene Ther 2000; 11:1165-76; PMID:10834618; http://dx.doi.org/10.1089/10430340050015211
   PubMed Web of Science ®Google Scholar
• Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T. In vitro construction of pseudovirions of human papillomavirus type 16: incorporation of plasmid DNA into reassembled L1/L2 capsids. J Virol 1998; 72:10298-300; PMID:9811779
   PubMed Web of Science ®Google Scholar
• Roden RB, Greenstone HL, Kirnbauer R, Booy FP, Jessie J, Lowy DR, Schiller JT. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol 1996; 70:5875-83; PMID:8709207
   PubMed Web of Science ®Google Scholar
• White WI, Wilson SD, Bonnez W, Rose RC, Koenig S, Suzich JA. In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J Virol 1998; 72:959-64; PMID:9444988
   PubMed Web of Science ®Google Scholar
• Smith LH, Foster C, Hitchcock ME, Leiserowitz GS, Hall K, Isseroff R, Christensen ND, Kreider JW. Titration of HPV-11 infectivity and antibody neutralization can be measured in vitro. J Invest Dermatol 1995; 105:438-44; PMID:7665926; http://dx.doi.org/10.1111/1523-1747.ep12321173
   PubMedGoogle Scholar
• Christensen ND, Kreider JW, Shah KV, Rando RF. Detection of human serum antibodies that neutralize infectious human papillomavirus type 11 virions. J Gen Virol 1992; 73 (Pt 5):1261-7; PMID:1316943; http://dx.doi.org/10.1099/0022-1317-73-5-1261
   PubMedGoogle Scholar
• Kemp TJ, Hildesheim A, Safaeian M, Dauner JG, Pan Y, Porras C, Schiller JT, Lowy DR, Herrero R, Pinto LA. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 2011; 29:2011-4; PMID:21241731; http://dx.doi.org/10.1016/j.vaccine.2011.01.001
   PubMed Web of Science ®Google Scholar
• Kemp TJ, Safaeian M, Hildesheim A, Pan Y, Penrose KJ, Porras C, Schiller JT, Lowy DR, Herrero R, Pinto LA. Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by cervarix((R)). Vaccine 2012; 31:165-70; PMID:23123024; http://dx.doi.org/10.1016/j.vaccine.2012.10.067
   PubMed Web of Science ®Google Scholar
• Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, Lowy DR, Wacholder S, Schiffman M, Rodriguez AC, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the costa rica vaccine trial. Cancer Prev Res (Phila) 2013; 6:1242-50; PMID:24189371; http://dx.doi.org/10.1158/1940-6207.CAPR-13-0203
   PubMed Web of Science ®Google Scholar
• Kemp TJ, Garcia-Pineres A, Falk RT, Poncelet S, Dessy F, Giannini SL, Rodriguez AC, Porras C, Herrero R, Hildesheim A, et al. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine 2008; 26:3608-16; PMID:18541349; http://dx.doi.org/10.1016/j.vaccine.2008.04.074
   PubMed Web of Science ®Google Scholar
• Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, FitzGerald PC, Kruger Kjaer S, Lowy DR, Schiller JT. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004; 321:205-16; PMID:15051381; http://dx.doi.org/10.1016/j.virol.2003.12.027
   PubMed Web of Science ®Google Scholar
• Buck CB, Pastrana DV, Lowy DR, Schiller JT. Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med 2005; 119:445-62; PMID:16350417
   PubMedGoogle Scholar
• Buck CB, Pastrana DV, Lowy DR, Schiller JT. Efficient intracellular assembly of papillomaviral vectors. J Virol 2004; 78:751-7; PMID:14694107; http://dx.doi.org/10.1128/JVI.78.2.751-757.2004
   PubMed Web of Science ®Google Scholar
• Sehr P, Rubio I, Seitz H, Putzker K, Ribeiro-Muller L, Pawlita M, Muller M. High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses. PLoS One 2013; 8:e75677; PMID:24124504; http://dx.doi.org/10.1371/journal.pone.0075677
   PubMed Web of Science ®Google Scholar
• LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, Janmohamed A, Kumakech E, Mosqueira NR, Nguyen NQ, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ 2011; 89:821-30B; PMID:22084528; http://dx.doi.org/10.2471/BLT.11.08986
   PubMed Web of Science ®Google Scholar
• Safaeian M, Kemp TJ, Pan DY, Porras C, Rodriguez AC, Schiffman M, Cortes B, Katki H, Wacholder S, Schiller JT, et al. Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the costa rica vaccine trial. Hum Vaccin Immunother 2013; 9:1399-406; PMID:23571174; http://dx.doi.org/10.4161/hv.24340
   PubMed Web of Science ®Google Scholar
• LaMontagne DS, Mugisha E, Pan Y, Kumakech E, Ssemaganda A, Kemp TJ, Cover J, Pinto LA, Safaeian M. Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in uganda. Vaccine 2014; PMID:25218297; doi: 10.1016/j.vaccine.2014.08.071
   PubMedGoogle Scholar
• Day PM, Pang YY, Kines RC, Thompson CD, Lowy DR, Schiller JT. A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies. Clin Vaccine Immunol 2012; 19:1075-82; PMID:22593236; http://dx.doi.org/10.1128/CVI.00139-12
   PubMed Web of Science ®Google Scholar
• Wu WH, Gersch E, Kwak K, Jagu S, Karanam B, Huh WK, Garcea RL, Roden RB. Capsomer vaccines protect mice from vaginal challenge with human papillomavirus. PLoS One 2011; 6:e27141; PMID:22069498; http://dx.doi.org/10.1371/journal.pone.0027141
   PubMedGoogle Scholar
• Buck CB, Thompson CD, Pang YY, Lowy DR, Schiller JT. Maturation of papillomavirus capsids. J Virol 2005; 79:2839-46; PMID:15709003; http://dx.doi.org/10.1128/JVI.79.5.2839-2846.2005
   PubMed Web of Science ®Google Scholar
• Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David MP, Poncelet SM, Pinto LA, Wettendorff MA. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 2008; 4:425-34; PMID:18948732; http://dx.doi.org/10.4161/hv.4.6.6912
   PubMed Web of Science ®Google Scholar